Add BrightSurf on Google Email

Study: New protocol for Treg expansion uses targeted immunotherapy to reduce transplant complications

A new protocol for Treg expansion uses targeted immunotherapy to reduce transplant complications, boosting survival rates while preserving anti-cancer immunity. The protocol, led by Robert Levy, uses TL1A-Ig fusion protein and low-dose IL-2 to stimulate specific receptors on Tregs, promoting a safer environment for stem cell transplants.

9/11 study shows how toxic exposures may lead to blood cancers

A study of 9/11 first responders found mutations in blood-forming cells may explain increased leukemia risk, suggesting a targeted intervention against environmental toxins. The research also identified IL1RAP as a protein culprit, which could be used to prevent or treat blood cancers in individuals exposed to similar disasters.

SourceAlbert Einstein College of Medicine·JournalCancer Discovery·TypeRandomized controlled/clinical trial·DateOct 1, 2025

Can digital health tools help younger cancer survivors better predict future health risks?

A groundbreaking study enrolls 465 AYA cancer patients to test if chatbot technology and digital education tools increase uptake of genetic counseling and improve patient outcomes. The trial aims to address longstanding gaps in genetic services for AYAs aged 18-39, who often receive care with limited access to genetic specialists.

SourceAlliance for Clinical Trials in Oncology·TypeRandomized controlled/clinical trial·DateSep 30, 2025

Using iron to destroy multiple myeloma cancer cells

Duke University researchers discovered that inhibiting an enzyme involved in iron regulation makes cancer cells vulnerable to cell death. By targeting STK17B kinase, they reactivated ferroptosis and increased the effectiveness of conventional therapies against multiple myeloma.

SourceDuke University·JournalBlood·TypeExperimental study·DateSep 24, 2025

Genetic screening technique could enhance CAR-T therapies for multiple myeloma and other cancers

Researchers identified genetic modifications that can improve the efficacy of chimeric antigen receptor (CAR)-T cell treatment for multiple myeloma and other cancers. The study used CRISPR screening to pinpoint genes that influenced T cell function and survival in culture and in a preclinical model of multiple myeloma.

SourceMass General Brigham·JournalNature·TypeExperimental study·DateSep 24, 2025

Study assesses cancers in children exposed to medical imaging

A study published in The New England Journal of Medicine found that nearly 4 million children and adolescents were at higher risk of developing blood cancers due to radiation exposure from medical imaging. The researchers estimated that up to 10% of pediatric blood and bone marrow cancers may be attributable to radiation exposure.

SourceUniversity of California - San Francisco·JournalNew England Journal of Medicine·DateSep 17, 2025

Genetic study suggests ways to catch blood cancer earlier

Researchers at WashU Medicine found that clonal hematopoiesis, a condition caused by mutated blood stem cells, is more common among individuals with inherited mutations that increase cancer risk. Those with inherited mutations had a higher risk of developing blood cancer if their stem cell clones acquired additional harmful mutations.

SourceWashU Medicine·JournalNature Genetics·DateAug 22, 2025

Effective therapy for MDS is vastly underused, especially in female and non-white patients

The study found that only 16% of newly diagnosed patients with MDS on Medicare received HMAs during the period analyzed, with women and non-white patients being less likely to start treatment. The analysis suggests that making changes with existing therapies and administration can have a huge impact on improving outcomes in high-risk MDS.

SourceAmerican Society of Hematology·JournalBlood Neoplasia·DateAug 6, 2025

Study: olutasidenib is highly effective in certain patients with myelodysplastic syndrome

Researchers found olutasidenib to be highly effective in patients with myelodysplastic syndrome (MDS) and IDH1 mutations. The study showed a response rate of 59% and improved blood count improvement, long duration of response, and overall survival rates. This breakthrough offers new treatment options for these patients.

Study shows DNA regulatory switch prompts stem cells to give rise to blood

A new study has found that TAF1 operates as a key molecular switch in adult hematopoietic stem cell maintenance and lineage commitment. This discovery challenges prevailing models of gene regulation and has the potential to lead to new therapeutic strategies targeting the molecule, which could improve blood production and transplantation.

SourceUniversity of Miami Miller School of Medicine·JournalDevelopmental Cell·DateJul 24, 2025

A breath test could help us detect blood cancers

A new breath test has been developed to detect blood cancers, showing promise for early diagnosis and treatment monitoring. The test uses exhaled breath analysis to identify molecules produced by cancer cells, potentially providing a quick and affordable diagnostic tool for areas with limited access to specialist equipment.

SourceQueen Mary University of London·JournalHemaSphere·TypeExperimental study·DateJul 22, 2025

The harmony of cells

A new bioinformatic tool called Cell Marker Accordion has been developed to help researchers understand single-cell analysis results. The tool reveals the presence of altered cells that may be linked to diseases such as blood cancers or solid tumours, and can identify unique genes involved in these alterations.

SourceUniversità di Trento·JournalNature Communications·DateJul 7, 2025

A new cell therapy for leukaemia shows high efficacy and safety in the laboratory

A new dual CAR-T cell therapy has been developed to target T-ALL, showing high efficacy and safety. The treatment targets two antigens simultaneously, making it more effective than previous therapies. Experimental results demonstrate its ability to control the disease in both laboratory and animal models, with an excellent safety profile.

SourceJosep Carreras Leukaemia Research Institute·JournalJournal of Hematology & Oncology·TypeExperimental study·DateJul 7, 2025